Skip to main content
logo
TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
34.09
-0.51 (-1.47%)
Apr 16, 2026, 1:56 PM EDT - Market open

TG Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
616.29329233.662.796.69
Revenue Growth (YoY)
87.32%40.80%8290.02%-58.36%4300.66%
Cost of Revenue
100.7138.4914.130.270.79
Gross Profit
515.57290.52219.532.525.9
Selling, General & Admin
232.03154.3122.7195.48128.09
Research & Development
160.2294.2976.19125.35222.58
Total Operating Expenses
392.25248.59198.9220.84350.67
Operating Income
123.3241.9320.63-218.32-344.77
Interest Expense
-26.73-24.03-12.62-10.19-5.64
Other Non-Operating Income (Expense)
10.797.695.044.72.31
Total Non-Operating Income (Expense)
-15.93-16.34-7.57-5.5-3.33
Pretax Income
107.3925.5913.06-223.81-348.1
Provision for Income Taxes
339.79-2.21-0.39--
Net Income
447.1823.3812.67-223.81-348.1
Net Income to Common
447.1823.3812.67-223.81-348.1
Net Income Growth
1812.41%84.52%---
Shares Outstanding (Basic)
144145142135132
Shares Outstanding (Diluted)
161160149135132
Shares Change (YoY)
0.67%7.96%9.67%2.41%14.64%
EPS (Basic)
3.100.160.09-1.65-2.63
EPS (Diluted)
2.770.150.09-1.65-2.63
EPS Growth
1746.67%66.67%---
Shares Outstanding
155.31155.84151.42146.39143.25
Free Cash Flow
-24.99-40.56-31.41-176.18-296.04
Free Cash Flow Per Share
-0.15-0.25-0.21-1.30-2.24
Gross Margin
83.66%88.30%93.95%90.48%88.19%
Operating Margin
20.01%12.74%8.83%-7838.99%-5154.28%
Profit Margin
72.56%7.11%5.42%-8036.34%-5204.08%
FCF Margin
-4.05%-12.33%-13.44%-6326.18%-4425.70%
EBITDA
123.384220.84-218.01-344.49
EBITDA Margin
20.02%12.76%8.92%-7828.11%-5150.07%
EBIT
123.3241.9320.63-218.32-344.77
EBIT Margin
20.01%12.74%8.83%-7838.99%-5154.28%
Effective Tax Rate
316.41%-8.64%-2.99%0.00%0.00%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q